05.04.16
Charles River Laboratories
1Q Revenues: $354.9 million (+20%)
1Q Earnings: $37.5 million (+19%)
Comments: Research Models and Services segment sales were $124.0 million in the quarter, up 3% driven by higher sales of both research models and research model services in North America, Europe, and Asia. Discovery and Safety Assessment segment revenues were $158.0 million, up 13% driven by growth in the Safety Assessment business. The Discovery Services business also grew, due primarily to the acquisition of Oncotest which contributed 2%. Manufacturing Support revenue was $72.9 million, up 21%, with the acquisitions of Celsis and Sunrise Farms contributing 15% to growth in the quarter. Revenue growth for the Biologics Testing Solutions business also contributed to theincrease.
1Q Revenues: $354.9 million (+20%)
1Q Earnings: $37.5 million (+19%)
Comments: Research Models and Services segment sales were $124.0 million in the quarter, up 3% driven by higher sales of both research models and research model services in North America, Europe, and Asia. Discovery and Safety Assessment segment revenues were $158.0 million, up 13% driven by growth in the Safety Assessment business. The Discovery Services business also grew, due primarily to the acquisition of Oncotest which contributed 2%. Manufacturing Support revenue was $72.9 million, up 21%, with the acquisitions of Celsis and Sunrise Farms contributing 15% to growth in the quarter. Revenue growth for the Biologics Testing Solutions business also contributed to theincrease.
